Andrew Cummins, MD
Gastroenterology · San Diego, CANPI 1699917096
Payments from drug & device makers
Across 390 payments — averaging $668.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$211K
- Teva Pharmaceuticals USA, Inc.$24K
- Genentech, Inc.$11K
- Adare Pharmaceuticals, Inc.$7K
- AbbVie$3K
- Johnson & Johnson$948
- plus $4K from 30 others
What the payments were for
- Food & beverage$8,00299%
- Education$631%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 7 | $210,733 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23,549 |
| Genentech, Inc. | 2 | $11,400 |
| Adare Pharmaceuticals, Inc. | 1 | $7,150 |
| AbbVie(2 entities) | 145 | $2,838 |
| Johnson & Johnson | 44 | $948 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $566 |
| Pfizer | 27 | $559 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 22 | $417 |
| Sanofi | 8 | $346 |
| Madrigal Pharmaceuticals | 9 | $288 |
| Regeneron Healthcare Solutions, Inc. | 10 | $282 |
| Gilead | 15 | $261 |
| Intercept Pharmaceuticals, Inc. | 11 | $209 |
| Ferring Pharmaceuticals Inc. | 7 | $138 |
| Shionogi Inc | 7 | $128 |
| Nestle Healthcare Nutrition Inc. | 5 | $119 |
| Aimmune Therapeutics, Inc. | 5 | $94 |
| Braintree Laboratories, Inc. | 4 | $93 |
| Medtronic | 2 | $90 |
| Lilly USA, LLC | 3 | $84 |
| Bristol Myers Squibb | 5 | $78 |
| Ironwood Pharmaceuticals, Inc | 4 | $74 |
| Romark Laboratories, LC | 4 | $70 |
| Vivus LLC | 3 | $58 |
| Capsovision, Inc. | 3 | $51 |
| Celltrion USA Inc. | 2 | $48 |
| Ardelyx, Inc. | 2 | $45 |
| Digestive Care, Inc. | 1 | $23 |
| Shire North American Group Inc | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Echosens North America, Inc. | 1 | $18 |
| QOL Medical, LLC | 1 | $17 |
| Axonics, Inc. | 1 | $17 |
| Orphalan Inc | 1 | $16 |
| Pentax Of America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rinvoq$125
How this compares
$260,858 in reported general payments places this provider in the 90th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 14 | $130,666 |
| VemlidyTenofovir Alafenamide | 26 | $47,252 |
| CreonLipase/Protease/Amylase | 15 | $37,538 |
| LinzessLinaclotide | 27 | $22,193 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 248 | $14,730 |
| PentasaMesalamine | 11 | $11,454 |
| Mesalamine | 14 | $10,995 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 14 | $2,413 |
| Omeprazole | 145 | $1,264 |
| Esomeprazole Magnesium | 16 | $1,036 |
| Pantoprazole Sodium | 42 | $405 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 21 | $355 |
| Famotidine | 23 | $291 |
| ConstuloseLactulose | 16 | $283 |
| Lactulose | 15 | $177 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Creon, Linzess | $2,838 | $190,39756 claims |
| GileadVemlidy | $261 | $47,25226 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $138 | $2,41314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,885 gastroenterology providers in California.
Other gastroenterology in San Diego
- Brigid BolandSan Diego$2.4M
- William SandbornSan Diego$2.2M
- Naveen GaraSan Diego$1.5M
- Michael BennettSan Diego$1.5M
- Taddese DestaSan Diego$1.4M
- Hyun KimSan Diego$1.3M
- Vijayalak PrathaSan Diego$1.2M
- David KunkelSan Diego$679K
- Peter WinkleCypress$116.7M
- Manuchehr DaraniSanta Ana$17.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.